ArticleNews reportPHN-04752026-10-31 22:04 CT

Dr Reddy's halts semaglutide supplies on impurity issue

Source · scanx.trade

TLDR

ScanX reports that Dr Reddy's Laboratories temporarily halted commercial semaglutide supplies after detecting an impurity during scale-up validation. The company targets resuming supplies in late October or early November and delivering 6–7 million pens across Q3 and Q4 of FY27, subject to successful validation and testing.

01—Key points

01Management says affected validation batches were not shipped commercially, so no product recall is required.
02The company must repeat validation with three new batches; oral semaglutide supplies and existing global regulatory filings are reportedly unaffected.
03Management expects lower near-term sales volumes and a possible OneSource inventory write-down, while retaining its long-term EBITDA margin target above 20%.

Why it matters Editorial

The reported quality issue delays commercial semaglutide supplies and introduces near-term financial uncertainty for Dr Reddy's and its manufacturing partner.

Read the original at scanx.trade↗

Summary generated with AI and reviewed by an editor. The original source governs; summaries can contain errors. Information only — not medical advice. Full disclaimer.